KYTX
NASDAQKyverna Therapeutics Inc.
Price$8.84+0.27 (+3.09%)
01:30 PM07:45 PM
News · 26 weeks51+33%
2026-03-012026-08-23
Mix1590d
- Insider5(33%)
- SEC Filings5(33%)
- Other4(27%)
- Leadership1(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsFDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026 Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026 Reiterates operating runway into 2028 EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy. The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential launches in stiff person syndrome (SPS) and general
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage TransitionEMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization. "Ritesh is a key addition to Kyverna as we prepare fo
- PRKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisMajority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date1 Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases,
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- INSIDERDirector Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Seidenberg Beth C was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERExecutive Chairperson Shaw Christi covered exercise/tax liability with 4,194 shares, decreasing direct ownership by 6% to 66,741 units (SEC Form 4) to cover taxes4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Aktar Mert was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 3 filed by new insider Martini Gregory S.3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Martini Gregory S.4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Names Greg Martini as Chief Financial OfficerEMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Greg Martini as Chief Financial Officer (CFO), effective May 18, 2026. Mr. Martini succeeds Dr. Marc Grasso who will be consulting for the Company to ensure a seamless transition. With this appointment, Mr. Martini will lead Kyverna's financial strategy and operations, including corporate finance, capital allocation, and investor relations, as the Company advances miv-cel (mivocabtagene autoleucel, KYV-101) toward a potential first approval in stiff
- PRKyverna Therapeutics to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences: H.C. Wainwright 4th Annual Nasdaq BioConnect Conference Format: Fireside chat and investor meetingsDate: Tuesday, May 19th, 2026Time: 2:30 p.m. ET Jefferies Global Healthcare Conference Format: Corporate presentation and investor meetingsDate: Wednesday, June 3rd, 2026Time: 3:10 p.m. ET Live webcasts of the presentations may be accessed via the Investors section of the Kyverna we
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial ResultsPositive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS demonstrated robust, durable effect in indication with no approved therapies; launch preparations continue with appointment of Nadia Dac as Chief Commercial Officer Enrollment advances in Phase 3 trial in generalized myasthenia gravis (gMG), further derisked by Phase 2 longer-term follow-up data demonstrating durable efficacy out to one year EMERYVILLE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on
- INSIDERSEC Form 4 filed by Chief Commercial Officer Dac Nadia4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dac Nadia3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
KYTX FAQ
6 questionsWhere does KYTX stock trade?
Kyverna Therapeutics Inc. (KYTX) is listed on NASDAQ.What sector and industry is KYTX in?
Kyverna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kyverna Therapeutics Inc. go public?
Kyverna Therapeutics Inc. (KYTX) completed its IPO in 2024.What are analysts saying about KYTX?
Kyverna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2025-08-20.What companies are similar to KYTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KYTX side-by-side with any of them on Quantisnow.How can I track KYTX on Quantisnow?
Quantisnow aggregates Kyverna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYTX to receive live email and push alerts on every new disclosure.